Bionomics Ltd Adr Stock Today
| BNOX Stock | USD 0.28 0.02 6.67% |
Performance1 of 100
| Odds Of DistressOver 85
|
Bionomics is trading at 0.28 as of the 3rd of December 2024; that is 6.67% down since the beginning of the trading day. The stock's open price was 0.3. Bionomics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Bionomics Ltd ADR are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of November 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of December 2021 | Category Healthcare | Classification Health Care |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. The company has 19.53 M outstanding shares of which 384.28 K shares are currently shorted by private and institutional investors with about 0.13 trading days to cover. More on Bionomics Ltd ADR
Moving together with Bionomics Stock
Moving against Bionomics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Bionomics Stock Highlights
| President CEO | Spyridon MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBionomics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bionomics' financial leverage. It provides some insight into what part of Bionomics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bionomics Ltd ADR (BNOX) is traded on NASDAQ Exchange in USA. It is located in 200 Greenhill Road, Eastwood, SA, Australia, 5063 and employs 8 people. Bionomics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.89 M. Bionomics ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 19.53 M outstanding shares of which 384.28 K shares are currently shorted by private and institutional investors with about 0.13 trading days to cover.
Bionomics Ltd ADR currently holds about 33.56 M in cash with (14.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.46, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bionomics Probability Of Bankruptcy
Ownership AllocationBionomics holds a total of 19.53 Million outstanding shares. Bionomics Ltd ADR retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bionomics Ownership Details
Bionomics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Investments Llc | 2024-09-30 | 0.0 | |
| Xtx Topco Ltd | 2024-09-30 | 0.0 | |
| Two Sigma Securities, Llc | 2024-09-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 1.6 M | |
| Point72 Asset Management, L.p. | 2024-09-30 | 316 K | |
| Susquehanna International Group, Llp | 2024-09-30 | 34.1 K | |
| Rhumbline Advisers | 2024-09-30 | 8.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 894 | |
| Northwestern Mutual Wealth Management Co | 2024-09-30 | 303 | |
| Aspire Private Capital, Llc | 2024-09-30 | 200 | |
| Lewis Asset Management Llc | 2024-09-30 | 0.0 |
Bionomics Historical Income Statement
Bionomics Stock Against Markets
Bionomics Corporate Management
| Elizabeth Doolin | Senior Development | Profile | |
| DCPSA FFPM | Consultant Neuroscience | Profile | |
| Errol Souza | Ex Chairman | Profile | |
| FCA BEC | Financial Controller | Profile | |
| FCIS BCom | Company Secretary | Profile | |
| MD DFAPA | Acting Officer | Profile |
Additional Tools for Bionomics Stock Analysis
When running Bionomics' price analysis, check to measure Bionomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionomics is operating at the current time. Most of Bionomics' value examination focuses on studying past and present price action to predict the probability of Bionomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionomics' price. Additionally, you may evaluate how the addition of Bionomics to your portfolios can decrease your overall portfolio volatility.